For the current week, the overall ratings of six Pharmaceutical stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, AstraZeneca (NYSE:AZN) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Astrazeneca is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. For Portfolio Grader’s specific subcategory of Sales Growth, AZN also gets an F. AZN shares are down 4.7% from the month prior. For more information, get Portfolio Grader’s complete analysis of AZN stock.
Depomed (NASDAQ:DEPO) gets weaker ratings this week as last week’s C drops to a D. Depomed is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that address large and growing markets and are based on proprietary oral drug delivery technologies. The stock gets F’s in Earnings Momentum, Equity, and Cash Flow. Margin Growth and Sales Growth also get F’s. The stock price has fallen 14.1% over the past month, worse than the 8.5% decrease the Nasdaq has seen over the same period of time. For a full analysis of DEPO stock, visit Portfolio Grader.
Avanir Pharmaceutical (NASDAQ:AVNR) experiences a ratings drop this week, going from last week’s C to a D. Avanir Pharmaceuticals engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. The stock gets F’s in Equity and Cash Flow. Share prices fell 32.3% over the past month. As of Nov. 16, 2012, 14.8% of outstanding Avanir Pharmaceutical shares were held short. To get an in-depth look at AVNR, get Portfolio Grader’s complete analysis of AVNR stock.
The rating of GlaxoSmithKline (NYSE:GSK) declines this week from a C to a D. GlaxoSmithKline is a research-based pharmaceutical company. Wall Street appears to agree with the stock downgrade, with share prices dropping 10.2% over the past month. For a full analysis of GSK stock, visit Portfolio Grader.
Pain Therapeutics (NASDAQ:PTIE) earns a D this week, moving down from last week’s grade of C. Pain Therapeutics develops safer or more efficacious drugs for use in pain management, particularly in the area of opioid painkillers. The stock also gets an F in Equity. Investors seem to agree with the downgrade and have pushed down the share price 49.1% over the past month. To get an in-depth look at PTIE, get Portfolio Grader’s complete analysis of PTIE stock.
Slipping from a C to a D rating, Ampio Pharmaceuticals (NASDAQ:AMPE) takes a hit this week. Ampio Pharmaceuticals engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. The stock gets F’s in Equity and Cash Flow. The stock price has fallen 11.5% over the past month. For more information, get Portfolio Grader’s complete analysis of AMPE stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
